Pediatric Cancer Therapy

Micafungin pharmacokinetics during febrile neutropenia determined

Published in Clinical Trials Week, September 5th, 2005

The pharmacokinetics of micafungin have determined in febrile neutropenic children undergoing cancer therapy.

"Micafungin (FK463) is a new parenteral echinocandin" antifungal agent, according to oncologists in the United States, who conducted a "multicenter, phase I, open-label, sequential-group dose escalation study" to "assess the safety, tolerability, and pharmacokinetics of micafungin in neutropenic pediatric patients."

"A total of 77 patients stratified by age (2 to 12 and 13 to 17 years) received micafungin," noted N.L. Seibel and coauthors at the National Cancer Institute. "Therapy was initiated at 0.5 mg/kg per day and escalated to higher...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Clinical Trials Week

Source: Clinical Trials Week (2005-09-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry